Cargando…

Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution

This study aimed to develop a physiologically‐based pharmacokinetic pharmacodynamic (PBPK/PD) parent‐metabolite model of edoxaban, an oral anticoagulant with a narrow therapeutic index, and to predict pharmacokinetic (PK)/PD profiles and potential drug–drug‐disease interactions (DDDIs) in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Ruijuan, Liu, Wenyuan, Ge, Weihong, He, Hua, Jiang, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431043/ https://www.ncbi.nlm.nih.gov/pubmed/37101392 http://dx.doi.org/10.1002/psp4.12977

Ejemplares similares

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
por: Siriez, Romain, et al.
Publicado: (2022)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine
por: Parasrampuria, Dolly A., et al.
Publicado: (2016)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability
por: Tsunoda, Shirley M., et al.
Publicado: (2021)

Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study
por: Ikushima, Ippei, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications
por: Sun, Lei, et al.
Publicado: (2023)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
por: Mendell, Jeanne, et al.
Publicado: (2013)

Pharmacokinetic and pharmacodynamic drug-drug interaction of Nomilin with atorvastatin in hyperlipidemic mice
por: Ding, Yan, et al.
Publicado: (2023)

Review of Tolvaptan’s Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions
por: Bhatt, Purav R., et al.
Publicado: (2014)

Comorbid epilepsy and depression—pharmacokinetic and pharmacodynamic drug interactions
por: Miziak, Barbara, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
por: Wei, Zhuodu, et al.
Publicado: (2023)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
por: Marok, Fatima Zahra, et al.
Publicado: (2023)

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling
por: Fuhr, Laura Maria, et al.
Publicado: (2022)

Oxycodone-Related Deaths: The Significance of Pharmacokinetic and Pharmacodynamic Drug Interactions
por: Jakobsson, Gerd, et al.
Publicado: (2022)

Rapid Assay for the Therapeutic Drug Monitoring of Edoxaban
por: Rashid, Md Abdur, et al.
Publicado: (2022)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?
por: Tod, M, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Evaluation of the Drug‐Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects
por: Desai, Amit, et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites
por: Darwish, Mona, et al.
Publicado: (2015)

Predicting drug–drug interactions through drug structural similarities and interaction networks incorporating pharmacokinetics and pharmacodynamics knowledge
por: Takeda, Takako, et al.
Publicado: (2017)

Response to “Quantitative Prediction of Drug‐Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is It Worth?”
por: Templeton, IE, et al.
Publicado: (2017)

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of Tyrosine Kinase Inhibitors
por: Xiu, Fangrui, et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?
por: Templeton, IE, et al.
Publicado: (2016)

Prediction of Drug–Drug–Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling
por: Kovar, Christina, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic drug interactions of carbamazepine and glibenclamide in healthy albino Wistar rats
por: Prashanth, S., et al.
Publicado: (2011)

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
por: Lee, Jieon, et al.
Publicado: (2014)

A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects
por: Jung, Jin Ah, et al.
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs
por: He, Hua, et al.
Publicado: (2019)

Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy
por: Kantae, Vasudev, et al.
Publicado: (2016)

Food Bioactive Compounds and Their Interference in Drug Pharmacokinetic/Pharmacodynamic Profiles
por: Briguglio, Matteo, et al.
Publicado: (2018)

Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges
por: Zou, Huixi, et al.
Publicado: (2020)

A pharmacokinetic–pharmacodynamic model based on multi-organ-on-a-chip for drug–drug interaction studies
por: Shinha, Kenta, et al.
Publicado: (2020)

Drug–drug interaction study of ciprofol and sodium divalproex: Pharmacokinetics, pharmacodynamics, and safety in healthy Chinese subjects
por: Yang, Dandan, et al.
Publicado: (2023)

Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
por: Nabeta, Takeru, et al.
Publicado: (2021)

Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis
por: Kloprogge, Frank, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
por: Gatti, Milo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s0bfm8ed0c03bg7ctnvi34ta1d